The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized multicenter phase II trial evaluating the sequencing of PD-1 inhibition with pembrolizumab (P) and standard platinum-based chemotherapy (C) in patients (pts) with metastatic non-small cell lung cancer (NSCLC) (AFT-09).
 
Thomas A. Hensing
Honoraria - Genentech/Roche
Consulting or Advisory Role - AstraZeneca/MedImmune; Takeda
Speakers' Bureau - Guardant Health
 
Xiaofei F. Wang
No Relationships to Disclose
 
Junheng Gao
No Relationships to Disclose
 
Tom Stinchcombe
Consulting or Advisory Role - AstraZeneca; G1 Therapeutics; G1 Therapeutics; Genentech/Roche; Novartis; Regeneron; Takeda
Research Funding - AstraZeneca (Inst); Blueprint Medicines (Inst); Genentech/Roche (Inst); Merck (Inst); Takeda (Inst)
 
Michael V. Knopp
No Relationships to Disclose
 
Arkadiusz Z. Dudek
Leadership - IGF Oncology; Martell diagnostic; Squarex Pharma; TTC Oncology
Stock and Other Ownership Interests - Biothera; IGF Oncology; Vanquish Oncology
Honoraria - AstraZeneca; Biothera; IGF Oncology; Martell diagnostic; Medtronic; Squarex Pharma; TTC Oncology; Vanquish Oncology
Consulting or Advisory Role - Biothera; TTC Oncology; Tychon; Vanquish Oncology
Research Funding - Lilly (Inst); Merck (Inst)
 
Stephen L. Graziano
No Relationships to Disclose
 
Jyoti D. Patel
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Takeda Science Foundation
 
Bryan Faller
No Relationships to Disclose
 
Konstantin H. Dragnev
Research Funding - G1 Therapeutics (Inst); Io Therapeutics (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); PharmaMar (Inst); Roche/Genentech (Inst)
 
David E. Kozono
No Relationships to Disclose
 
Everett E. Vokes
Stock and Other Ownership Interests - Coordination Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Biolumina; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Lilly; Merck; Novartis; Regeneron